Can a simple blood test predict who will respond to lung cancer therapy?
NCT ID NCT07244016
First seen Jan 05, 2026 · Last updated Jun 22, 2026 · Updated 32 times
Summary
This study is looking at whether a special test that analyzes immune cells (called T cell repertoire technology) can predict how well a combination of the drug tislelizumab and standard chemotherapy works for people with extensive-stage small cell lung cancer. The study will follow 40 patients who have not yet been treated for their cancer. The main goal is to see if the test can predict how long patients live without their cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hosipital
RECRUITINGZhengzhou, Henan, 450000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors predict which lung cancer patients will benefit most from tislelizumab combined with chemotherapy, leading to more personalized treatment.
What could go wrong
This is a small, early observational study (40 people) that is not testing a new treatment itself. The predictive technology may not prove accurate enough for routine use.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.